Analysts Conflicted on These Healthcare Names: Agios Pharma (NASDAQ: AGIO), Agilent (NYSE: A) and Atara Biotherapeutics (NASDAQ: ATRA)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agios Pharma (NASDAQ: AGIO), Agilent (NYSE: A) and Atara Biotherapeutics (NASDAQ: ATRA).

Agios Pharma (NASDAQ: AGIO)

In a report released today, Anupam Rama from J.P. Morgan maintained a Buy rating on Agios Pharma (NASDAQ: AGIO), with a price target of $85. The company’s shares opened today at $79.37, close to its 52-week high of $82.96.

According to TipRanks.com, Rama is a 4-star analyst with an average return of 14.6% and a 55.4% success rate. Rama covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Alexion Pharmaceuticals, and Sarepta Therapeutics.

Currently, the analyst consensus on Agios Pharma is Strong Buy and the average price target is $85.75, representing an 8.0% upside.

In a report released yesterday, RBC Capital also reiterated a Buy rating on the stock with a $88 price target.
Agilent (NYSE: A)

In a report released today, Tycho Peterson from J.P. Morgan maintained a Buy rating on Agilent (NYSE: A), with a price target of $80. The company’s shares opened today at $74.94, close to its 52-week high of $75.

According to TipRanks.com, Peterson is a 4-star analyst with an average return of 7.0% and a 59.6% success rate. Peterson covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Accelerate Diagnostics, and DENTSPLY SIRONA Inc.

Currently, the analyst consensus on Agilent is Strong Buy and the average price target is $76.57, representing a 2.2% upside.

In a report released today, Jefferies also reiterated a Buy rating on the stock with a $81 price target.
Atara Biotherapeutics (NASDAQ: ATRA)

Citigroup analyst Yigal Nochomovitz downgraded Atara Biotherapeutics (NASDAQ: ATRA) to Sell today. The company’s shares opened today at $42.85.

According to TipRanks.com, Nochomovitz is a 4-star analyst with an average return of 7.7% and a 48.5% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Merrimack Pharmaceuticals, and Anthera Pharmaceuticals.

Atara Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $44.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.